表紙:脳インプラントの世界市場-2023年~2030年
市場調査レポート
商品コード
1345388

脳インプラントの世界市場-2023年~2030年

Global Brain Implants Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.36円
脳インプラントの世界市場-2023年~2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

脳インプラントの世界市場は、2022年に53億米ドルに達し、2030年には108億米ドルに達し、有利な成長が予測されています。脳インプラントの世界市場は、予測期間中(2023-2030年)にCAGR 9.5%を示すと予測されています。

脳インプラントは、脳と直接インターフェースし、神経活動と外部機器間の通信を可能にする可能性があるため、さまざまな分野で重要な位置を占めています。ワイヤレス技術の進歩により、脳インプラントは物理的なコネクタを必要とせずに外部機器と通信できるようになっています。この動向は、脳インプラントを使用する際の快適性や快適性を向上させると同時に、有線接続に伴う感染症やその他の合併症のリスクを軽減することを目的としていました。

さらに、神経変性疾患や精神疾患の増加、手頃な価格で効果的かつ永続的な治療法に対するアンメット需要もあります。脳インプラントの市場規模は、脳神経外科医や神経クリニックが脳インプラントの認知度を高めるために努力を重ねている結果、拡大しています。

ダイナミクス

神経疾患の有病率の上昇

神経疾患の増加が市場拡大に寄与しています。例えば、脳組織に電極を埋め込むことで、脳の様々な部位の信号を刺激したり記録したりすることができます。パーキンソン病は、脳インプラント、特に脳深部刺激療法(DBS)を用いて頻繁に治療されています。パーキンソン病は神経変性疾患であり、ドーパミンを産生する脳細胞の進行性の減少が特徴です。

振戦、こわばり、徐脈(動作が遅い)、姿勢不安定などの運動症状は、このドーパミンの枯渇によってもたらされます。パーキンソン病の症状は、異常な脳活動によって引き起こされるが、電気刺激はこれを抑制するのに役立ちます。したがって、パーキンソン病の増加は市場の拡大に寄与しています。

例えば、Parkinson's Foundationによると、パーキンソン病(PD)は米国で約100万人が罹患しています。2030年には、この数は120万人に達すると予想されています。アルツハイマー病に次いで、パーキンソン病は最も一般的な神経変性疾患です。米国では、毎年9万人近くがパーキンソン病と診断されています。世界では1,000万人以上がPDに苦しんでいます。このように、神経疾患の増加は市場の拡大に寄与しています。

各社の主な発展戦略

脳インプラントに関連する製品承認、製品上市、共同研究、買収の増加は、市場への新規技術に対する需要の増加に起因します。例えば、2022年10月、神経疾患をより効果的に治療するために、ニューロテクノロジー企業Axoftが開発したブレイン・マシン・インターフェース(BMI)がFDAのブレークスルー・デバイスに指定されました。同事業は、FDAの前臨床調査を支援し、「脳のように柔らかい」神経インプラントのプロトタイプをスケールアップするため、800万米ドルの資金を調達しました。

さらに2023年5月26日、イーロン・マスクと神経技術事業ニューラリンクの共同設立者は、食品医薬品局(FDA)が同社に初の人体内臨床試験の許可を与えたと発表しました。ニューラリンク社が開発中の脳インプラント「リンク」は、重度の麻痺を持つ人が神経信号のみで外部技術を操作できるようにすることを意図しています。このことは、ALSのような末期の変性疾患を持つ人々が、いつの日か頭でタイプしたりカーソルを動かしたりする能力を取り戻す可能性を示唆しています。以上のような要因から、市場は予測期間中に拡大すると思われます。

治療に伴う高コスト

脳インプラントの開発と移植には多額の費用がかかります。外科的治療、術後ケア、将来的なガジェットの交換などがすべて価格に含まれます。例えば、脳インプラントの価格はメーカーによって異なります。手術の価格(移植装置、病院費用、麻酔を含む)は、米国では35,000米ドルから100,000米ドルに達します。

技術へのアクセスは、特に金銭的余裕のない人々にとっては、価格によって妨げられるかもしれないです。さらに、脳インプラントを埋め込むには、経験豊富な神経外科医と最先端機器を備えた手術室を必要とする、高度に洗練された外科技術が必要です。手術、麻酔、術後ケアには多額の費用がかかります。したがって、上記の要因が市場の成長を抑制することになります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 神経疾患の有病率の上昇
      • 各社の主な発展戦略
    • 抑制要因
      • 治療に伴う高コスト
    • 機会
      • 精神疾患の治療に新たな道
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 脳深部刺激装置
  • 脊髄刺激装置
  • 迷走神経刺激装置

第8章 材料別

  • シリコン
  • タングステン
  • 白金-イリジウム
  • ナノチューブ
  • その他

第9章 用途別

  • アルツハイマー病 l
  • パーキンソン病
  • てんかん
  • 慢性疼痛
  • その他

第10章 エンドユーザー別

  • 病院
  • 神経クリニック
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Medtronic PLC
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Boston Scientific Corporation
  • Renishaw PLC
  • Synchron Inc
  • Abbott Laboratories
  • LivaNova PLC
  • NeuroPace Inc
  • Sapiens Neuro
  • Neuralink
  • Nexstim

第14章 付録

目次
Product Code: MD6755

Overview

The Global Brain Implants Market reached US$ 5.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 10.8 billion by 2030. The global brain implants market is expected to exhibita CAGR of 9.5% during the forecast period (2023-2030).

Brain implants hold significant importance across various fields due to their potential to interface directly with the brain and enable communication between neural activity and external devices. Advances in wireless technology were enabling brain implants to communicate with external devices without the need for physical connectors. The trend aimed to improve the comfort and comfort of using brain implants while also reducing the risk of infection or other complications associated with wired connections.

In addition, there is an increasing number of neurodegenerative and mental illnesses, as well as an unmet demand for affordable, effective, and permanent therapies. The market size for brain implants is growing as a result of increasing effort being made by neurosurgeons and neurology clinics to increase awareness of brain implants.

Dynamics

The Rising Prevalence of Neurological Diseases

The increase in neurological disorders contributes to the market's expansion. For instance, one can stimulate or record signals from various parts of the brain by implanting electrodes in the brain tissue. Parkinson's disease is frequently treated using brain implants, specifically Deep Brain Stimulation (DBS). Parkinson's disease is a neurodegenerative condition marked by a progressive loss of brain cells that produce dopamine.

Motor symptoms like tremors, stiffness, bradykinesia (slow movement), and postural instability are brought on by this dopamine depletion. The Parkinson's symptoms are caused by aberrant brain activity, which the electrical stimulation helps control. Thus, the rise in Parkinson's disease contributes to the market's expansion.

For instance, according to Parkinson's Foundation, stated that, Parkinson's disease (PD) affects around one million persons in the US. By 2030, it is anticipated that this number would reach 1.2 million. After Alzheimer's disease, Parkinson's disease is the most common neurodegenerative condition. In the United States, PD is yearly diagnosed in close to 90,000 individuals. Over 10 million people worldwide suffer with PD. Thus, the increase in neurological illnesses contributes to the market's expansion.

Key Development Strategies Followed by the Companies

The increase in the product approvals, product launches, collaborations and acquisitions related to brain implants owing to its increasing demand to novel technologies to the market. For instance, in October 2022, in order to more effectively treat neurological illnesses, the brain-machine interface (BMI) developed by the neurotechnology company Axoft was designated an FDA Breakthrough Device. The business raised $8 million in funding to support pre-clinical FDA research and scale up prototypes of its "soft as the brain" neural implants.

Additionally, on May 26, 2023, Elon Musk and his co-founders at the neurotech business Neuralink announced that the Food and Drug Administration had given the company permission to carry out its first in-human clinical investigation. The Link, a brain implant being developed by Neuralink, intends to enable individuals with severe paralysis to operate external technology only utilizing neural signals. This suggests that people with terminal degenerative illnesses like ALS may someday regain the ability to type and move cursors with their minds. Due of the above factors the market will expand in forecast period.

High Cost Associated with the Treatment

Brain implants can be costly to develop and implant. Surgical treatments, post-operative care, and prospective gadget replacements are all included in the price. For instance, different manufacturers charge different prices for brain implants. The price of surgery (including the implanted device, hospital expenses, and anesthesia) can range from $35,000 to $100,000 in the United States.

Access to the technology may be hampered by the price, especially for those who cannot afford it. Additionally, placing brain implants requires highly sophisticated surgical techniques that call for experienced neurosurgeons and an operating theater outfitted with cutting-edge equipment. Surgery, anesthesia, and post-operative care can come at a significant financial expense. Thus above factors will restrain the market growth.

Segment Analysis

The global brain implants market is segmented based ontype, material, application, end user and region.

The Alzheimer's Disease Accounted for Approximately 31.07% of the Brain Implants Market Share

Dementia, a condition marked by memory loss and cognitive decline, is one of the main causes of dementia. ReTypes are needed for diagnosis, treatment, care, and support services for affected people, placing a significant load on healthcare systems. Age is the major risk factor for Alzheimer's disease. A larger portion of the population is at an elevated risk of contracting the disease as the world's population continues to age. An individual's risk increases as they age.

The intricate combination of genetic, environmental, and lifestyle factors affects the risk of Alzheimer's disease. These elements may combine as people get older, raising the risk that they may have the illness. Thus, the increase in the elderly population drives segment growth.

For instance, according to Eurostat, the EU population in January 2022, was estimated to be 446.7 million, out of which 21.1% were Older individuals aged 65 or over indicating an increase of 0.3 percentage points (pp) to the previous year and an increase of 3.1 pp compared with a decade earlier.

In addition, according to a new report by the United Nations (UN), the number of individuals aged 65 years or above globally is anticipated to increase two folds in the next 30 years. The geriatric population is expected to attain 1.6 billion in 2050, making up over 16% of the world population. By thus increasing the geriatric population will drive the segment growth.

Geographical Penetration

North America Accounted for Approximately 42.6% of the Market Share in 2022

The brain implant market is dominated by North America. Due to the regulations that make healthcare inexpensive for the vast majority of the population in the region, the nation's healthcare facilities are of the greatest quality and are accessible to the wide population. The prevalence and incidence of numerous neurological illnesses are rising, which will accelerate the growth of the region.

For instance, according to Alzheimer's Association, more than 6 million Americans of all ages have Alzheimer's. In 2023, there will be 6.7 million Americans 65 and older who have Alzheimer's. 73% of people are 75 years of age or older. The proportion of Americans who have Alzheimer's disease or another kind of dementia will increase along with the size of the population in the United States who are 65 years of age and older. Barring technological advances that prevent or treat Alzheimer's disease, the estimated number of persons aged 65 and older with the condition may increase to 12.7 million by 2050.

Thus, the demand for neurological treatments including brain implants is fueled by the need to identify and treat these diseases, which is anticipated to lead to a growth in the number of product manufacturing companies in the nation. The market in the North American region has grown as a result of the rise in neurological diseases.

Competitive Landscape

The major global players in the brain implants market Medtronic PLC, Boston Scientific Corporation, Renishaw PLC, Synchron Inc, Abbott Laboratories, LivaNova PLC, NeuroPace Inc, Sapiens Neuro, Neuralink, Nexstim and others.

COVID-19 Impact Analysis

The covid has affected negatively due to several factors. The danger of infection is present throughout any surgical operation, including brain implant surgeries. Since COVID-19 is extremely contagious, catching it while having a brain implant could result in serious illness or difficulties.Access to medical care has been hampered throughout numerous locations due to the pandemic.

Due of COVID-19's impact on the healthcare system, people with brain implants may have trouble getting timely treatment or device changes. In many hospitals, brain implant surgery, such as DBS, is an elective surgical procedure, hence the scheduled surgeries have been postponed. When the restrictions were eased, procedures were carried out and patients were advised to maintain their most recent optimal dosing schedule.

By Type

  • Deep Brain Stimulator
  • Spinal Cord Stimulator
  • Vagus Nerve Stimulator

By Material

  • Silicon
  • Tungsten
  • Platinum-iridium
  • Nanotubes
  • Others

By Application

  • Alzheimer's Disease
  • Parkinson's Disease
  • Epilepsy
  • Chronic Pain
  • Others

By End User

  • Hospitals
  • Neurology clinics
  • Others

By Region

  • North America

U.S.

Canada

Mexico

  • Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

  • South America

Brazil

Argentina

Rest of South America

  • Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

  • Middle East and Africa

Key Developments

  • In May 2022, in order to allow six severely paralyzed people to operate digital gadgets hands-free and with only their thoughts, Elon Musk's competitor firm Neuralink, Synchron, has started conducting human trials on the subject. The US-based Synchron competes with Elon Musk's Neuralink, which also seeks to let paralyzed people to use computers and phones through its brain activities alone. Both companies create endovascular brain-computer interfaces (BCIs).
  • In March 2021, one of the largest investments in the European medical nanotechnology sector to date has been made in a collaboration between two Barcelona institutions and the Nanomedicine Lab at The University of Manchester to treat brain disorders such as epilepsy and Parkinson's Disease.
  • In December 2022, the Eterna spinal cord stimulation (SCS) system from Abbott, the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain, received FDA approval. The only SCS waveform technology with the greatest level of clinical proof (1A evidence), low-dose BurstDR stimulation, is used in Eterna SCS and has been shown to relieve pain 23% more than conventional waveform technology methods.

Why Purchase the Report?

  • To visualize the global brain implants market segmentation based on type, material, application, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of brain implants market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global brain implants market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Material
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising prevalence of neurological diseases
      • 4.1.1.2. Key Development Strategies Followed by the Companies
    • 4.1.2. Restraints
      • 4.1.2.1. High cost associated with the treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. New avenues for treating mental health conditions
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. ByType

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Deep Brain Stimulator*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Spinal Cord Stimulator
  • 7.4. Vagus Nerve Stimulator

8. ByMaterial

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 8.1.2. Market Attractiveness Index, By Material
  • 8.2. Silicon*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Tungsten
  • 8.4. Platinum-iridium
  • 8.5. Nanotubes
  • 8.6. Others

9. ByApplication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Alzheimer's Disease l*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parkinson's Disease
  • 9.4. Epilepsy
  • 9.5. Chronic Pain
  • 9.6. Others

10. ByEnd User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Neurology clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Medtronic PLC*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Boston Scientific Corporation
  • 13.3. Renishaw PLC
  • 13.4. Synchron Inc
  • 13.5. Abbott Laboratories
  • 13.6. LivaNova PLC
  • 13.7. NeuroPace Inc
  • 13.8. Sapiens Neuro
  • 13.9. Neuralink
  • 13.10. Nexstim

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us